{"id":"moxonidine-physiotens","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5","effect":"Fatigue"},{"rate":"3-5","effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL19236","moleculeType":"Small molecule","molecularWeight":"241.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxonidine acts as a central-acting antihypertensive by selectively stimulating imidazoline-1 (I1) receptors in the rostral ventrolateral medulla of the brainstem. This activation suppresses sympathetic outflow, leading to decreased peripheral vascular resistance and reduced blood pressure. It has greater selectivity for I1 receptors compared to older alpha-2 agonists, potentially resulting in fewer central nervous system side effects.","oneSentence":"Moxonidine is a selective imidazoline-1 receptor agonist that reduces sympathetic nervous system activity to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:41.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Essential hypertension"},{"name":"Hypertension in patients with metabolic syndrome or diabetes"}]},"trialDetails":[{"nctId":"NCT04050410","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2019-08-27","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT05312892","phase":"PHASE1, PHASE2","title":"Sympathetic Mechanisms in Obesity-Crossover Design","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-20","conditions":"Obesity, Hypertension","enrollment":12},{"nctId":"NCT04329806","phase":"PHASE1","title":"Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity","status":"TERMINATED","sponsor":"Italo Biaggioni","startDate":"2021-02-23","conditions":"Obesity-Associated Insulin Resistance","enrollment":10},{"nctId":"NCT01094769","phase":"PHASE4","title":"Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Baker Heart and Diabetes Institute","startDate":"2011-04","conditions":"Diabetic Nephropathies","enrollment":48},{"nctId":"NCT04474899","phase":"PHASE4","title":"Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension","status":"UNKNOWN","sponsor":"Royal Perth Hospital","startDate":"2015-06-24","conditions":"Obesity, Hypertension","enrollment":120},{"nctId":"NCT04479813","phase":"PHASE4","title":"Role of Sympathetic Activation in Ischemia Reperfusion Injury","status":"COMPLETED","sponsor":"Royal Perth Hospital","startDate":"2015-07-08","conditions":"Central Sympathetic Nervous System Diseases","enrollment":46},{"nctId":"NCT05147753","phase":"PHASE4","title":"Moxonidine Effects on Neuropeptide Y","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2010-01-11","conditions":"Obesity, Hypertension","enrollment":90},{"nctId":"NCT02355821","phase":"NA","title":"Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women","status":"COMPLETED","sponsor":"National Research Center for Preventive Medicine","startDate":"2015-04","conditions":"Osteopenia, Arterial Hypertension","enrollment":114},{"nctId":"NCT04023565","phase":"PHASE4","title":"Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Sergey V. Nedogoda","startDate":"2019-03-11","conditions":"Arterial Hypertension, Metabolic Syndrome","enrollment":120},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01504321","phase":"PHASE4","title":"Polycystic Ovary Syndrome - Improving Outcomes","status":"COMPLETED","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Polycystic Ovary Syndrome","enrollment":42},{"nctId":"NCT01791699","phase":"PHASE4","title":"Moxonidine for Prevention of Post-ablation AFib Recurrences","status":"COMPLETED","sponsor":"Spyridon Deftereos","startDate":"2012-08","conditions":"Atrial Fibrillation","enrollment":150},{"nctId":"NCT01180231","phase":"PHASE4","title":"Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity","status":"UNKNOWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2010-09","conditions":"Obesity, Overweight","enrollment":77},{"nctId":"NCT00518479","phase":"NA","title":"Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2003-09","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":42},{"nctId":"NCT01138423","phase":"PHASE4","title":"Treatment of Adiposity Related hypErTension (TARGET)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2010-08","conditions":"Hypertension, Abdominal Obesity, Metabolic Syndrome","enrollment":32},{"nctId":"NCT01360710","phase":"PHASE4","title":"The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension","status":"UNKNOWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-01","conditions":"Abdominal Obesity, Hypertension","enrollment":100},{"nctId":"NCT00244504","phase":"PHASE3","title":"Moxonidine in Patients Undergoing Vascular Surgery","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2002-11","conditions":"Cardiac Disease, Vascular Surgery","enrollment":141},{"nctId":"NCT00424801","phase":"NA","title":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-01","conditions":"Microvascular Angina, Hypertension","enrollment":10},{"nctId":"NCT00160277","phase":"PHASE3","title":"Efficacy and Safety of Moxonidine in Indian Patients","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2005-07","conditions":"Hypertension","enrollment":100},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":"Hypertension, Type 2 Diabetes","enrollment":440}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"FIBROSIS"},{"count":1,"reaction":"NEPHROGENIC FIBROSING DERMOPATHY"},{"count":1,"reaction":"SKIN FIBROSIS"},{"count":1,"reaction":"THROMBOPHLEBITIS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Physiotens"],"phase":"marketed","status":"active","brandName":"Moxonidine (Physiotens)","genericName":"Moxonidine (Physiotens)","companyName":"Baker Heart and Diabetes Institute","companyId":"baker-heart-and-diabetes-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxonidine is a selective imidazoline I1-receptor agonist that reduces sympathetic nervous system activity to lower blood pressure. Used for Essential hypertension, Hypertension in patients with metabolic syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}